Tag: monoclonal antibody
There is a new drug that promises to have fewer side effects
Bristol-Myers Squibb has approved its drug Cobenfy for the treatment of schizophrenia. It aims to reduce the negative symptoms like apathy and lack of motivation. It will be available from October at $1,850 a month, according to the company. Cobenfy is a monoclonal antibody that binds to muscarinic receptors, a group of receptors found in the gut and the brain.
Read More